Efficacy and Safety of Prunus Mume and Choline in Patients with Abnormal Level of Liver Function Test
Total Page:16
File Type:pdf, Size:1020Kb
International Journal of Clinical Trials Aslam MN et al. Int J Clin Trials. 2020 Aug;7(3):170-175 http://www.ijclinicaltrials.com pISSN 2349-3240 | eISSN 2349-3259 DOI: http://dx.doi.org/10.18203/2349-3259.ijct20203103 Original Research Article Efficacy and safety of Prunus mume and choline in patients with abnormal level of liver function test Muhammad N. Aslam1, Anwar Ali2, Suresh Kumar3* 1Department of Gastroenterology, Mayo Hospital, Lahore, Pakistan 2Department of Medicine, Saidu Group of Teaching Hospital, Khyber Pakhtunkhwa, Pakistan 3Department of Medicine, Rafa-e-Aam Hospital, Sindh, Pakistan Received: 18 March 2020 Revised: 27 April 2020 Accepted: 30 April 2020 *Correspondence: Dr. Suresh Kumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: The objectives of the study were to determine the efficacy and safety of Prunus mume and choline in patients with abnormal liver function test. Methods: This open labelled, multi-centered observational study was done for a from May 2019 to December 2019. Patients of either gender, above 18 years of age having elevated levels of aspartate aminotransferase, alanine transaminase or gamma-glutamyltransferase were included in the study after taking informed consent. One to two tablets of revolic per day were given preferably in the morning with breakfast or as per instructions of the physician. Patient follow-ups were done at 2nd and 4th week after treatment. SPSS version 20.0 was used for analysis. Frequency and percentages and for quantitative data, mean, standard deviation, median and interquartile range were recorded. Wilcoxon signed ranks test was applied with p value of <0.05 as significant level. Results: Among 247 patients, male to female ratio was 2:1 with overall mean age of 42.8±12.6 years. Total bilirubin decreased from baseline to week-4 in treatment with Prunus mume extract and choline (p=0.04). Median and IQR of alanine transaminase levels also reduced substantially from 99 (52) to 42 (36.5) I/U. Aspartate aminotransferase levels significantly decreased from 78.5 (57) to 40 (29) I/U. Overall at the end of treatment on week-4, 26 (10.5%) patients experienced gastrointestinal distress, 25 (10.1%) anorexia, 14 (5.7%) excessive salivation and 29 (11.7%) patients experienced excessive sweating. Conclusions: This study reported significant improvement in alanine transaminase and aspartate aminotransferase levels after treatment with Prunus mume extract and choline (revolic). It is safe and effective to use them for deranged liver functions tests. Keywords: Prunus mume extract, Choline, Liver function tests INTRODUCTION cause of chronic liver disease.2 Other lifestyle-associated risk factors include diabetes, obesity, smoking and non- Among various hepatic disorders, the most commonly alcoholic steato-hepatitis. Although substantial observed liver diseases are non-alcoholic fatty liver improvements have been made in treatment modalities disease, steato-hepatitis and hepatocellular carcinoma.1 through medications, yet the mortality rates have not Even though multiple causes of liver diseases have been shown significant improvements and so therefore, newer associated with it, infection with hepatitis B and hepatitis therapeutic strategies are the utmost need for putting an C especially in under-developed and developing countries end to such devastating disease.3 is highest. In developed world, alcohol is the leading International Journal of Clinical Trials | July-September 2020 | Vol 7 | Issue 3 Page 170 Aslam MN et al. Int J Clin Trials. 2020 Aug;7(3):170-175 Until recently, oxidative stress was reported to be one of phospholipids or are oxidized and used as methyl group the main risk factors for liver disease.4 Many herbal donor.14 The hepatic metabolite of choline is extracts having anti-oxidant activity like allium sativum, phosphatidylcholine, which is essentially important for glycyrrhizaglabra, taxacumofficinale, silybummarianum packaging, export of triglycerides in very low density and cichoriumintybus, all are studies for the beneficial lipoprotein and for bile salt solubility to be secreted.15 effect on a variety of diseases including hepatic disorders.5 Prunus mume, originating from south-eastern Multiple studies have been conducted outside the country China, is known as an anti-inflammatory and anti- but there is little data in Pakistan to support for the oxidative fruit. Extract of Prunus mume is an herbal effectiveness of Prunus mume and choline. Therefore, the variant that has been reported to exert a potentially objective of this study was to determine the safety and therapeutic effect for various conditions such as efficacy of Prunus mume and choline in patients with inflammatory bowel disease, diabetes mellitus, vascular abnormal level of liver function tests. dementia and cancers, including hepato-cellular carcinoma.6 METHODS Prunus mume is regarded to contain 5-O-caffeoylquinic This open labeled, multi-centered observational study acidand 3-O-caffeoylquinic acid, both found to be a was done for a period of 06 months from May 2019 to major bioactive anti-oxidant compound.7 Prunus mume December 2019 by using convenient sampling technique. has been observed to be an effective treatment modality The study was conducted in Mayo Hospital, Lahore, in alcoholic liver disease having elevations in serum as Saidu Group of Teaching Hospital, Swat and Rafa-e-Aam well as hepatic triglycerides where serum triglycerides Hospital, Karachi. Using openEpi software, the sample were reported to reduce in treatment with Prunus mume. size calculator version 3.01 was used and using 47% It could be used for preventing alcoholic liver steatosis. efficacy of drug, at 07% margin of error and 95% Additionally, Prunus mume was seen to reduce cellular confidence interval, a sample size of 196 was calculated. oxidative stress through inhibition of mitogen-activated Total of 247 patients were included in the study.16 protein kinase’s activation and p-53 mediated apoptotic axis of signaling. This resulted in inhibiting hepatic After taking written informed consent and the study will steatosis and apoptosis as well.8 be carried out in compliance with the protocols and the principles of the Declaration of Helsinki, and in The constituents of Prunus mume, also known as accordance with the International Conference on Japanese apricot included triterpenoids, like oleanolic Harmonization harmonized tripartite guideline for good acid and ursolic acid, which has reported to inhibit clinical practice. Patients of either gender, above 18 years cellular growth and induce multiple tumors’ cell death, of age having elevated levels of aspartate such as in gastric cancer, pro-myelocytic leukemia, aminotransferase (AST), alanine transaminase (ALT) or pancreatic cancer, breast cancer, colon cancer, malignant gamma-glutamyl transferase (GGT), were included in the myeloma, esophageal cancer, lung cancer and hepato- study. Patients with obstructive jaundice, pregnant and cellular cancer.9 Lately, the hepato-protective effects of lactating mothers, having presence of underlying chronic Prunus mume have been observed in patients among renal failure were excluded from the study. chronic liver disease patients.10 Patients were given one to two tablets revolic per day, Since choline is used in synthesis of acetylcholine, a preferably in the morning with breakfast or as per neurotransmitter as well as involved in methyl-group instructions of the physician. The changes of serum ALT metabolism, especially in the liver. Therefore, the major and AST at baseline, 2nd week and 04th week of treatment site of choline metabolism is the liver, were it is mainly were noted after treatment with Prunus mume and found as phosphatidylcholine.11 It is associated with choline. Similarly, changes in (GGT) were also noted. assembly / secretion of lipoproteins and to solubilize The proportion of patients experiencing any adverse cholesterol in bile. The link between choline deficiency event such as gastrointestinal distress, anorexia, and accumulation of hepatic lipid has been recognized for salivation and sweating after taking the tablets were noted over 50 years, leading to the fact that choline-deficient and reported. These study parameters and sample size diets ought to induce non-alcoholic fatty liver disease. was selected in accordance with the study performed by Little is known regarding choline’s role in potentially Beretta et al in 2016.16 preventing or in treating non-alcoholic fatty liver disease.12,13 SPSS version 20.0 was used for analysis of data. For qualitative data, frequency in percentages was reported Choline is a content of cell membrane, mitochondrial and for quantitative data, mean, standard deviation, membrane and also an important component of median and interquartile range was recorded. Wilcoxon neurotransmitter, acetylcholine. Due to its essential signed ranks test was applied to test for significant ubiquitous presence in cellular components and difference at baselineweek-02 and week-04 keeping p- pathways, it is regarded as a main nutrient in metabolism value of <0.05 as statistically significant. and through phosphorylation are used to producing International Journal of Clinical Trials | July-September 2020 | Vol 7 | Issue 3 Page 171 Aslam MN et al. Int J Clin Trials. 2020 Aug;7(3):170-175 RESULTS The median and IQR (inter-quartile range) of total bilirubin was 1.1(2.3) mg/dl at week-2 (p=0.04). ALT In a total of 247 patients, 170 (69.1%) male and 77 was 99 (52) I/U at baseline, 61 (43) mg/dl at week-2 (30.9%) were included in the study. Patients were divided (p<0.01) and 42 (36.5) mg/dl at week-4 (p<0.01). AST into age groups with most common age group of above was 78.50 (57) I/U at baseline, 50 (32) mg/dl at week-2 50 years with the frequency of 68 (27.5%).